Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $55 from $54 and keeps a Buy rating on the shares. The firm says the company has a key clinical catalyst this quarter with readout of the Phase 3 RECONNECT trial in Fragile X syndrome. The data could materially drive shares if positive and “presents asymmetric risk-reward to the upside,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences resumed with a Neutral at Goldman Sachs
- Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205
- Harmony Biosciences presents preclinical data for BP1.15205
- Promising Developments in Harmony Biosciences Justify Buy Rating
- Harmony Biosciences settles generic drug litigation, strengthens patent